Literature DB >> 23721650

Mood and anxiety disorders across the adult lifespan: a European perspective.

R D McDowell1, A Ryan1, B P Bunting2, S M O'Neill2, J Alonso3, R Bruffaerts4, R de Graaf5, S Florescu6, G Vilagut7, J M C de Almeida8, G de Girolamo9, J M Haro10, H Hinkov11, V Kovess-Masfety12, H Matschinger13, T Tomov14.   

Abstract

BACKGROUND: The World Mental Health Survey Initiative (WMHSI) has advanced our understanding of mental disorders by providing data suitable for analysis across many countries. However, these data have not yet been fully explored from a cross-national lifespan perspective. In particular, there is a shortage of research on the relationship between mood and anxiety disorders and age across countries. In this study we used multigroup methods to model the distribution of 12-month DSM-IV/CIDI mood and anxiety disorders across the adult lifespan in relation to determinants of mental health in 10 European Union (EU) countries.
METHOD: Logistic regression was used to model the odds of any mood or any anxiety disorder as a function of age, gender, marital status, urbanicity and employment using a multigroup approach (n = 35500). This allowed for the testing of specific lifespan hypotheses across participating countries.
RESULTS: No simple geographical pattern exists with which to describe the relationship between 12-month prevalence of mood and anxiety disorders and age. Of the adults sampled, very few aged ≥ 80 years met DSM-IV diagnostic criteria for these disorders. The associations between these disorders and key sociodemographic variables were relatively homogeneous across countries after adjusting for age.
CONCLUSIONS: Further research is required to confirm that there are indeed stages in the lifespan where the reported prevalence of mental disorders is low, such as among younger adults in the East and older adults in the West. This project illustrates the difficulties in conducting research among different age groups simultaneously.

Entities:  

Mesh:

Year:  2013        PMID: 23721650     DOI: 10.1017/S0033291713001116

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  5 in total

1.  Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys.

Authors:  R C Kessler; N A Sampson; P Berglund; M J Gruber; A Al-Hamzawi; L Andrade; B Bunting; K Demyttenaere; S Florescu; G de Girolamo; O Gureje; Y He; C Hu; Y Huang; E Karam; V Kovess-Masfety; S Lee; D Levinson; M E Medina Mora; J Moskalewicz; Y Nakamura; F Navarro-Mateu; M A Oakley Browne; M Piazza; J Posada-Villa; T Slade; M Ten Have; Y Torres; G Vilagut; M Xavier; Z Zarkov; V Shahly; M A Wilcox
Journal:  Epidemiol Psychiatr Sci       Date:  2015-02-27       Impact factor: 6.892

Review 2.  Strengths and Weaknesses of the Gray Mouse Lemur (Microcebus murinus) as a Model for the Behavioral and Psychological Symptoms and Neuropsychiatric Symptoms of Dementia.

Authors:  Fabien Pifferi; Jacques Epelbaum; Fabienne Aujard
Journal:  Front Pharmacol       Date:  2019-10-30       Impact factor: 5.810

3.  Prevalence and associated factors of DSM-5 insomnia disorder in the general population of Qatar.

Authors:  Salma Mawfek Khaled; Catalina Petcu; Maryam Ali Al-Thani; Aisha Mohammed H A Al-Hamadi; Suhad Daher-Nashif; Monica Zolezzi; Peter Woodruff
Journal:  BMC Psychiatry       Date:  2021-02-08       Impact factor: 3.630

4.  Urbanicity, biological stress system functioning and mental health in adolescents.

Authors:  Brittany E Evans; Anja C Huizink; Kirstin Greaves-Lord; Joke H M Tulen; Karin Roelofs; Jan van der Ende
Journal:  PLoS One       Date:  2020-03-18       Impact factor: 3.240

5.  Psychological distress, anxiety, family violence, suicidality, and wellbeing in New Zealand during the COVID-19 lockdown: A cross-sectional study.

Authors:  Susanna Every-Palmer; Matthew Jenkins; Philip Gendall; Janet Hoek; Ben Beaglehole; Caroline Bell; Jonathan Williman; Charlene Rapsey; James Stanley
Journal:  PLoS One       Date:  2020-11-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.